297 related articles for article (PubMed ID: 38262506)
1. The perspective of cAMP/cGMP signaling and cyclic nucleotide phosphodiesterases in aortic aneurysm and dissection.
Shu T; Zhou Y; Yan C
Vascul Pharmacol; 2024 Mar; 154():107278. PubMed ID: 38262506
[TBL] [Abstract][Full Text] [Related]
2. Roles of phosphodiesterases in the regulation of the cardiac cyclic nucleotide cross-talk signaling network.
Zhao CY; Greenstein JL; Winslow RL
J Mol Cell Cardiol; 2016 Feb; 91():215-27. PubMed ID: 26773602
[TBL] [Abstract][Full Text] [Related]
3. Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.
Kelly MP
Cell Signal; 2018 Jan; 42():281-291. PubMed ID: 29175000
[TBL] [Abstract][Full Text] [Related]
4. Cyclic nucleotide signalling compartmentation by PDEs in cultured vascular smooth muscle cells.
Zhang L; Bouadjel K; Manoury B; Vandecasteele G; Fischmeister R; Leblais V
Br J Pharmacol; 2019 Jun; 176(11):1780-1792. PubMed ID: 30825186
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase in heart and vessels: from physiology to diseases.
Fu Q; Wang Y; Yan C; Xiang YK
Physiol Rev; 2024 Apr; 104(2):765-834. PubMed ID: 37971403
[TBL] [Abstract][Full Text] [Related]
6. Contribution of phosphodiesterase isoenzymes and cyclic nucleotide efflux to the regulation of cyclic GMP levels in aortic smooth muscle cells.
Mercapide J; Santiago E; Alberdi E; Martinez-Irujo JJ
Biochem Pharmacol; 1999 Nov; 58(10):1675-83. PubMed ID: 10535760
[TBL] [Abstract][Full Text] [Related]
7. Cyclic nucleotide compartmentalization: contributions of phosphodiesterases and ATP-binding cassette transporters.
Cheepala S; Hulot JS; Morgan JA; Sassi Y; Zhang W; Naren AP; Schuetz JD
Annu Rev Pharmacol Toxicol; 2013; 53():231-53. PubMed ID: 23072381
[TBL] [Abstract][Full Text] [Related]
8. Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors.
Schoeffter P; Lugnier C; Demesy-Waeldele F; Stoclet JC
Biochem Pharmacol; 1987 Nov; 36(22):3965-72. PubMed ID: 2825708
[TBL] [Abstract][Full Text] [Related]
9. Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.
Zhao CY; Greenstein JL; Winslow RL
J Mol Cell Cardiol; 2015 Nov; 88():29-38. PubMed ID: 26388264
[TBL] [Abstract][Full Text] [Related]
10. Cyclic nucleotide phosphodiesterases in rabbit detrusor smooth muscle.
Qiu Y; Kraft P; Craig EC; Liu X; Haynes-Johnson D
Urology; 2002 Jan; 59(1):145-9. PubMed ID: 11796312
[TBL] [Abstract][Full Text] [Related]
11. "cAMP-specific" phosphodiesterase contributes to cGMP degradation in cerebellar cells exposed to nitric oxide.
Bellamy TC; Garthwaite J
Mol Pharmacol; 2001 Jan; 59(1):54-61. PubMed ID: 11125024
[TBL] [Abstract][Full Text] [Related]
12. Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus.
Suvarna NU; O'Donnell JM
J Pharmacol Exp Ther; 2002 Jul; 302(1):249-56. PubMed ID: 12065724
[TBL] [Abstract][Full Text] [Related]
13. Advances, Perspectives and Potential Engineering Strategies of Light-Gated Phosphodiesterases for Optogenetic Applications.
Tian Y; Yang S; Gao S
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066112
[TBL] [Abstract][Full Text] [Related]
14. Evidence for the activity of five adenosine-3',5'-monophosphate-degrading phosphodiesterase isozymes in the adult rat neocortex.
Sutor B; Mantell K; Bacher B
Neurosci Lett; 1998 Aug; 252(1):57-60. PubMed ID: 9756358
[TBL] [Abstract][Full Text] [Related]
15. Apicomplexan phosphodiesterases in cyclic nucleotide turnover: conservation, function, and therapeutic potential.
Moss WJ; Brusini L; Kuehnel R; Brochet M; Brown KM
mBio; 2024 Feb; 15(2):e0305623. PubMed ID: 38132724
[TBL] [Abstract][Full Text] [Related]
16. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
Cheng J; Grande JP
Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
[TBL] [Abstract][Full Text] [Related]
17. Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases.
Kokkonen K; Kass DA
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():455-479. PubMed ID: 27732797
[TBL] [Abstract][Full Text] [Related]
18. Cyclic nucleotide phosphodiesterases in heart and vessels: A therapeutic perspective.
Bobin P; Belacel-Ouari M; Bedioune I; Zhang L; Leroy J; Leblais V; Fischmeister R; Vandecasteele G
Arch Cardiovasc Dis; 2016; 109(6-7):431-43. PubMed ID: 27184830
[TBL] [Abstract][Full Text] [Related]
19. Novel roles of cAMP/cGMP-dependent signaling in platelets.
Smolenski A
J Thromb Haemost; 2012 Feb; 10(2):167-76. PubMed ID: 22136590
[TBL] [Abstract][Full Text] [Related]
20. Cyclic nucleotide phosphodiesterases (PDEs): coincidence detectors acting to spatially and temporally integrate cyclic nucleotide and non-cyclic nucleotide signals.
Maurice DH; Wilson LS; Rampersad SN; Hubert F; Truong T; Kaczmarek M; Brzezinska P; Freitag SI; Umana MB; Wudwud A
Biochem Soc Trans; 2014 Apr; 42(2):250-6. PubMed ID: 24646226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
